Kymera Therapeutics GAAP EPS of -$0.62 beats by $0.12, revenue of $65M beats by $32.22M

Kymera Therapeutics (KYMR) Q2 2026 earnings: GAAP EPS beat and revenue surged on Gilead option fee and Sanofi milestone.